Source: OpenFDA label data · Not medical advice · For personal tracking only
Important warning themes extracted from the FDA label. Review the full label warnings below for source wording.
BOXED WARNING WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ] Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [see Dosage and Administration (2.3), Contraindications (4), Warnings and Precautio ns (5.1) ] If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting Prompt haemodialysis is recommended [see Warnings and Precautions (5.1) ] WARNING: LACTIC ACIDOSIS See full prescribing information for complete boxed warning Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio and metformin plasma levels generally >5 mcg/mL (5.1) Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information (5.1) If lactic acidosis is suspected, discontinue Metformin Hydrochloride Extended-Release Tablets and institute general supportive measures in a hospital setting Prompt hemodialysis is recommended (5.1)
These may signal more serious reactions and may require prompt medical attention.
Frequently reflected in adverse reaction or label text.
Pain, cramping, or aching in the stomach or belly area.
Show full FDA warning text
Source label wording. This may be long, technical, or formatted for the original package label.
BOXED WARNING WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias
The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain
Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio
and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ]
Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g
Show FDA label use text
Technical label wording. It may be incomplete, repetitive, or written for clinicians.
Show FDA label dosage text
Not dosing guidance. Follow your clinician, pharmacist, or product label.
carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment
Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [see Dosage and Administration (2.3), Contraindications (4), Warnings and Precautio ns (5.1) ]
If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting
Prompt haemodialysis is recommended [see Warnings and Precautions (5.1) ]
WARNING: LACTIC ACIDOSIS See full prescribing information for complete boxed warning
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias
Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain
Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio
and metformin plasma levels generally >5 mcg/mL
(5.1) Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment
Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information
(5.1) If lactic acidosis is suspected, discontinue Metformin Hydrochloride Extended-Release Tablets and institute general supportive measures in a hospital setting
Prompt hemodialysis is recommended
(5.1)